Does Lowering LDL-C to Ultra-Low Levels Provide Additional Benefit?
The researchers observed these endpoints according to degree of LDL cholesterol reduction after 1 month of treatment.
The researchers observed these endpoints according to degree of LDL cholesterol reduction after 1 month of treatment.
Compared with CABG, PCI was associated with similar risks of all-cause mortality, and with elevated risks of coronary heart disease mortality, myocardial infarction, and repeat revascularization.
This is an investigational use for Eliquis.
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
Researchers concluded that the use of statins is the likely cause of this diagnosis appearing to be beneficial against breast cancer development and subsequent death.
After adjusting for age and gender, patients randomized to the aggressive treatment arm demonstrated triple the risk of mortality from any cause vs. patients who received less intense treatment (4.9% vs. 1.7%, hazard ratio [HR] 3.12, 95% CI: 1.00-9.69; P=0.012).
Several sub-studies investigated the superior efficacy of spironolactone in RHTN and whether there was potential benefit with amiloride in the same population.
Change in apoB levels may be better predictor of clinical response than LDL-C, HDL-C levels
Four cups a day could reduce risk by 64 percent, researchers say
MRAs such as spironolactone and eplerenone are “still underused in routine clinical practice” but can be effective in countering the harms of high aldosterone levels, explained study author Professor Farzin Beygui, MD, PhD.